Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies

Kaiser Health News, 17 January 2017
Author: Sarah Jane Tribble and Sydney Lupkin
“A Kaiser Health News investigation shows that the system intended to help desperate patients is being manipulated by drugmakers to maximize profits and to protect niche markets for medicines already being taken by millions. The companies aren’t breaking the law but they are using the Orphan Drug Act to their advantage in ways that its architects say they didn’t foresee or intend. Today, many orphan medicines, originally developed to treat diseases affecting fewer than 200,000 people, come with astronomical price tags.”
Find article here.